Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EnteraBio has released positive results from a Phase 1 clinical evaluating its oral osteoporosis drug.
Subscribe to our email newsletter
Oramed Pharmaceuticals has licensed the product to EnteraBio in 2010, under which Oramed is eligible to get 3% royalties plus a small holding in the company.
The trial involved 12 healthy volunteers and was at the Hadasah Medical Center in Jerusalem.
The results from the Phase 1 trial supports the continued development of Entera’s oral osteoporosis drug.